Travere Therapeutics (TVTX) Acquisitions (2014 - 2016)

Travere Therapeutics' Acquisitions history runs 3 years deep, the most recent figure standing at $115000.0 for Q4 2016.

• Quarterly Acquisitions changed N/A year-over-year to $115000.0 in Q4 2016, while the trailing twelve-month figure through Dec 2017 was $115000.0 (down 81.3% YoY) and the FY2020 annual result came in at $95.3 million, changed N/A from the prior year.
• Acquisitions was $115000.0 for Q4 2016 at Travere Therapeutics, down from $500000.0 in the prior quarter.
• Across five years, Acquisitions topped out at $33.4 million in Q1 2015 and bottomed at $115000.0 in Q4 2016.
• A 3-year average of $15.8 million and a median of $14.8 million in 2014 frame the typical range for Acquisitions.
• Peak annual rise in Acquisitions reached 14.68% in 2015, while the deepest fall reached 14.68% in 2015.
• Travere Therapeutics' Acquisitions stood at $29.2 million in 2014, then climbed by 14.68% to $33.4 million in 2015, then tumbled by 99.66% to $115000.0 in 2016.
• Business Quant data shows TVTX's Acquisitions at $115000.0 in Q4 2016, $500000.0 in Q2 2016, and $33.4 million in Q1 2015.